SCHEMBL4067268

SCHEMBL4067268

CCNC(C)Cc1cccc(C(NC(=O)OCc2ccccc2)C2OC=CO2)c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 11/20 0.46
TSHR P16473 8/20 0.46
ALDH1A1 P00352 4/20 0.45
CYP2C9 P11712 3/20 0.45
CYP2C19 P33261 3/20 0.45
CYP1A2 P05177 3/20 0.45
POLB P06746 1/20 0.45
CYP2D6 P10635 1/20 0.45
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CTSL P07711 1/20 0.42
CTSS P25774 1/20 0.42
ATM Q13315 1/20 0.42
TRPM8 Q7Z2W7 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
MAPK1 P28482 1/20 0.41
PPARG P37231 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4059561 0.90 CYP3A4 (0.48) CYP3A4TSHRALDH1A1CYP2C9CYP2C19
SCHEMBL4062359 0.81 CYP3A4 (0.41) CYP3A4TSHRALDH1A1CYP2C9CYP2C19
SCHEMBL4064784 0.76 SIGMAR1 (0.35) TSHRALDH1A1CYP2C19CYP1A2CYP2D6
SCHEMBL14396307 0.74 BCHE (0.51) CYP3A4TSHRLMNASMN1; SMN2CTSL
SCHEMBL14396308 0.74 BCHE (0.51) CYP3A4TSHRLMNASMN1; SMN2CTSL
SCHEMBL14396353 0.74 BCHE (0.50) CYP3A4TSHRCTSLCTSSATM
SCHEMBL4062861 0.71 ACE (0.45) CTSLCTSSATM
SCHEMBL14396493 0.71 BCHE (0.45) CYP3A4TSHRALDH1A1CYP2C9CYP2C19
SCHEMBL14396495 0.71 BCHE (0.45) CYP3A4TSHRALDH1A1CYP2C9CYP2C19
SCHEMBL4067265 0.71 SIGMAR1 (0.43) LMNASMN1; SMN2ATMTRPM8SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569676-B2 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2009-08-04 US disclosed
EP-1498415-B1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs ROCHE DIAGNOSTICS GMBH (DE) 2007-06-27 EP disclosed
US-7060847-B2 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2006-06-13 US disclosed
US-20050153439-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs GHOSHAL MITALI (US) 2005-07-14 US disclosed
US-20050014210-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs ROCHE DIAGNOSTICS CORPORATION 2005-01-20 US disclosed
EP-1498415-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs Roche Diagnostics GmbH (DE) 2005-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014210-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs DRD3, SLC6A3, DRD2 CYP3A4 796/4885TSHR 4264/4885ALDH1A1 944/4885
US-20050153439-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs DRD3, SLC6A3, DRD2 CYP3A4 796/4885TSHR 4264/4885ALDH1A1 944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.